Precision BioSciences (DTIL) Expected to Announce Quarterly Earnings on Tuesday

Precision BioSciences (NASDAQ:DTIL) is projected to issue its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect Precision BioSciences to post earnings of ($0.85) per share and revenue of $1.38 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 3, 2026 at 9:30 AM ET.

Precision BioSciences (NASDAQ:DTIL) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.46). Precision BioSciences had a negative return on equity of 72.52% and a negative net margin of 96.73%. On average, analysts expect Precision BioSciences to post ($3.33) EPS for the current fiscal year and ($1.86) EPS for the next fiscal year.

Precision BioSciences Price Performance

Shares of NASDAQ DTIL opened at $7.06 on Monday. The company has a current ratio of 12.82, a quick ratio of 12.82 and a debt-to-equity ratio of 0.50. The firm’s 50-day moving average is $6.90 and its 200-day moving average is $6.50. Precision BioSciences has a 1 year low of $3.53 and a 1 year high of $9.62. The firm has a market capitalization of $194.86 million, a PE ratio of -2.52 and a beta of 1.34.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on DTIL. Wall Street Zen downgraded Precision BioSciences from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Precision BioSciences in a research note on Wednesday, August 5th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Precision BioSciences in a research report on Monday, August 3rd. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Precision BioSciences has a consensus rating of “Moderate Buy” and a consensus price target of $32.25.

Precision BioSciences Company Profile

Precision BioSciences, Inc is a biotechnology company developing gene-editing medicines using its proprietary ARCUS platform. ARCUS is based on engineered DNA-cutting enzymes designed to make targeted changes to genetic material, with the potential to remove, insert or correct DNA sequences in human cells.

The company’s research and development activities have focused primarily on in vivo gene editing, in which therapeutic editing components are delivered directly into the body. Its development programs have included potential treatments for conditions such as chronic hepatitis B infection, Duchenne muscular dystrophy and certain rare genetic disorders.